Fulgent Genetics Inc Cash Flow Conversion Efficiency
Fulgent Genetics Inc cash flow conversion efficiency. Based on the latest financial reports, Fulgent Genetics Inc (FLGT) has a cash flow conversion efficiency ratio of -0.024x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-23.76 Million) by net assets ($995.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Fulgent Genetics Inc (2014–2025)
Cash flow conversion efficiency of Fulgent Genetics Inc from 2014 to 2025. This chart illustrates how Fulgent Genetics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Fulgent Genetics Inc for real-time trading data and today's change.
Fulgent Genetics Inc Cash Flow Conversion Ratio Explained
Fulgent Genetics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Fulgent Genetics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fulgent Genetics Inc ranked by their cash flow conversion efficiency. Also see FLGT market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CJ ENM CO. Ltd
KQ:035760
|
0.103x |
|
Jiangsu Liba Enterprise Joint-Stock Co Ltd
SHG:603519
|
0.055x |
|
MK Restaurant Group Public Company Limited
BK:M
|
0.049x |
|
Universal Cement Corp
TW:1104
|
0.030x |
|
STINGRAY GROUP INC.
F:317A
|
N/A |
|
REGAL PARTNERS LTD.
F:OC7
|
N/A |
|
Shenandoah Telecommunications Co
NASDAQ:SHEN
|
0.025x |
|
Kunshan Top A Intelligent Equipment
SHE:300836
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Fulgent Genetics Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Fulgent Genetics Inc from 2014 to 2025. Review cash generation quality of Fulgent Genetics Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.11 Billion | $-101.64 Million | -0.092x | -592.40% |
| 2024-12-31 | $1.13 Billion | $21.06 Million | 0.019x | -21.72% |
| 2023-12-31 | $1.13 Billion | $27.00 Million | 0.024x | -88.07% |
| 2022-12-31 | $1.27 Billion | $253.52 Million | 0.200x | -56.78% |
| 2021-12-31 | $1.17 Billion | $538.58 Million | 0.462x | +87.04% |
| 2020-12-31 | $569.39 Million | $140.63 Million | 0.247x | +270.57% |
| 2019-12-31 | $82.78 Million | $5.52 Million | 0.067x | +616.11% |
| 2018-12-31 | $52.27 Million | $-675.00K | -0.013x | -152.42% |
| 2017-12-31 | $54.03 Million | $1.33 Million | 0.025x | -69.53% |
| 2016-12-31 | $54.48 Million | $4.41 Million | 0.081x | +142.94% |
| 2015-12-31 | $5.15 Million | $-969.00K | -0.188x | +92.79% |
| 2014-12-31 | $1.68 Million | $-4.40 Million | -2.611x | -- |
About Fulgent Genetics Inc
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pa… Read more